memantine and Memory Disorders
memantine has been researched along with Memory Disorders in 68 studies
Memory Disorders: Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"In the 1-year extension phase the favourable effect of adjunctive memantine on memory was sustained and we observed further improvement of negative, positive and overall symptoms in patients with clozapine-treated refractory schizophrenia." | 9.24 | Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. ( de Haan, L; Deijen, JB; Schulte, PF; Veerman, SR, 2017) |
"Clozapine-treated patients with refractory schizophrenia were randomly assigned to 12 weeks of double-blind adjunctive treatment with memantine (n = 26) or placebo (n = 26)." | 9.22 | Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. ( de Haan, L; Schulte, PF; Smith, JD; Veerman, SR, 2016) |
"Our study supports the hypothesis that drugs with antagonistic properties on the NMDA receptor, such as memantine, might be efficient in treatment of major depression." | 7.88 | Effectiveness of memantine on depression-like behavior, memory deficits and brain mRNA levels of BDNF and TrkB in rats subjected to repeated unpredictable stress. ( Amidfar, M; Kim, YK; Wiborg, O, 2018) |
" In this research, we show the effects of lithium and memantine on spatial memory and neuroinflammation in an Aβ1-42 oligomers-induced animal model of dementia in rats." | 7.85 | Lithium and memantine improve spatial memory impairment and neuroinflammation induced by β-amyloid 1-42 oligomers in rats. ( Batista-Silva, H; Belletini-Santos, T; Budni, J; Feijó, DP; Garcez, ML; Krasilchik, LR; Luz, AP; Mina, F; Quevedo, J; Schiavo, GL, 2017) |
" Furthermore, we evaluated the effect of anti-dementia drugs memantine, a NMDA antagonist, and donepezil, a cholinesterase inhibitor, on OKA ICV induced memory impairment." | 7.76 | Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity. ( Kamat, PK; Nath, C; Saxena, G; Shukla, R; Tota, S, 2010) |
"Treatment with memantine appeared to have differential effects on cognitive performance in a population of women with putative risk factors for AD." | 6.74 | Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study. ( Holcomb, M; Kenna, HA; Lazzeroni, L; Powers, BN; Rasgon, NL; Williams, KE; Wroolie, TE, 2009) |
"Memantine (Mem) is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist used in the treatment of Alzheimer's disease." | 5.62 | [Effects of Yokukansankachimpihange on Memantine-induced Dizziness in Mice with Memory Impairment]. ( Aoki, Y; Han, LK; Kaneda, M; Michihara, S; Shimoyama, T; Takahashi, R, 2021) |
"Memantine treatment improved spatial and recognition memory performance in the Ts65Dn mice, though not to the level of normosomic littermate controls." | 5.37 | Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. ( Bimonte-Nelson, H; Boger, H; Granholm, AC; Lockrow, J, 2011) |
"In the 1-year extension phase the favourable effect of adjunctive memantine on memory was sustained and we observed further improvement of negative, positive and overall symptoms in patients with clozapine-treated refractory schizophrenia." | 5.24 | Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. ( de Haan, L; Deijen, JB; Schulte, PF; Veerman, SR, 2017) |
"Clozapine-treated patients with refractory schizophrenia were randomly assigned to 12 weeks of double-blind adjunctive treatment with memantine (n = 26) or placebo (n = 26)." | 5.22 | Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. ( de Haan, L; Schulte, PF; Smith, JD; Veerman, SR, 2016) |
"Our study supports the hypothesis that drugs with antagonistic properties on the NMDA receptor, such as memantine, might be efficient in treatment of major depression." | 3.88 | Effectiveness of memantine on depression-like behavior, memory deficits and brain mRNA levels of BDNF and TrkB in rats subjected to repeated unpredictable stress. ( Amidfar, M; Kim, YK; Wiborg, O, 2018) |
" In this research, we show the effects of lithium and memantine on spatial memory and neuroinflammation in an Aβ1-42 oligomers-induced animal model of dementia in rats." | 3.85 | Lithium and memantine improve spatial memory impairment and neuroinflammation induced by β-amyloid 1-42 oligomers in rats. ( Batista-Silva, H; Belletini-Santos, T; Budni, J; Feijó, DP; Garcez, ML; Krasilchik, LR; Luz, AP; Mina, F; Quevedo, J; Schiavo, GL, 2017) |
" Furthermore, we evaluated the effect of anti-dementia drugs memantine, a NMDA antagonist, and donepezil, a cholinesterase inhibitor, on OKA ICV induced memory impairment." | 3.76 | Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity. ( Kamat, PK; Nath, C; Saxena, G; Shukla, R; Tota, S, 2010) |
"Treatment with memantine appeared to have differential effects on cognitive performance in a population of women with putative risk factors for AD." | 2.74 | Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study. ( Holcomb, M; Kenna, HA; Lazzeroni, L; Powers, BN; Rasgon, NL; Williams, KE; Wroolie, TE, 2009) |
"The modern era of drug development for Alzheimer's disease began with the proposal of the cholinergic hypothesis of memory impairment and the 1984 research criteria for Alzheimer's disease." | 2.50 | Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. ( Andreasen, N; Feldman, H; Giacobini, E; Jones, R; Kivipelto, M; Mangialasche, F; Mantua, V; Mecocci, P; Pani, L; Schneider, LS; Winblad, B, 2014) |
"Memantine is a moderate affinity, uncompetitive NMDA receptor antagonist with strong voltage-dependency and fast kinetics." | 2.44 | Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. ( Danysz, W; Parsons, CG; Stöffler, A, 2007) |
"Current therapies in Alzheimer's disease (AD), including Memantine, have proven to be only symptomatic but not curative or disease modifying." | 1.62 | Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer's Disease. ( Bouchet, M; Couly, S; Denus, M; Maurice, T; Rubinstenn, G, 2021) |
"Memantine (Mem) is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist used in the treatment of Alzheimer's disease." | 1.62 | [Effects of Yokukansankachimpihange on Memantine-induced Dizziness in Mice with Memory Impairment]. ( Aoki, Y; Han, LK; Kaneda, M; Michihara, S; Shimoyama, T; Takahashi, R, 2021) |
"Memantine treatment was able both to reverse the memory deficits and to reduce the excessive intake of palatable diet and the withdrawal-induced hypophagia in food cycling rats." | 1.56 | Withdrawal from Extended, Intermittent Access to A Highly Palatable Diet Impairs Hippocampal Memory Function and Neurogenesis: Effects of Memantine. ( Abdullatif, AA; Cottone, P; Ferragud, A; Sabino, V; Velázquez-Sánchez, C, 2020) |
"In this study, chronic administration of memantine with melatonin improved episodic memory in the object recognition test and reduced the number of amyloid aggregates and reactive microgliosis in the brains of 5xFAD mice." | 1.51 | Effects of the drug combination memantine and melatonin on impaired memory and brain neuronal deficits in an amyloid-predominant mouse model of Alzheimer's disease. ( Beniashvili, A; Jürgenson, M; Morozova, M; Noortoots, A; Zapolski, M; Zharkovskaja, T; Zharkovsky, A, 2019) |
"Memantine treatment ameliorated the spatial memory deficits induced, as evidenced by the MWM tests." | 1.51 | N-(p-amylcinnamoyl) anthranilic acid attenuates remedial effects of memantine on memory deficits following intracerebroventricular streptozotocin administration in rats. ( Demiryürek, AT; Demiryürek, Ş; Göl, M; Kaplan, DS; Örkmez, M; Saracaloğlu, A, 2019) |
"Pretreatment with memantine offered protection to both juvenile and adult animals." | 1.48 | Radiation induces age-dependent deficits in cortical synaptic plasticity. ( Bronk, L; Dougherty, PM; Duman, JG; Grosshans, DR; Lam, TT; Ma, D; Wang, Q; Weng, C; Zhang, D; Zhou, W, 2018) |
"Memantine has been approved for moderate to severe AD, but evidence indicates that it does not modify disease progression." | 1.43 | Insulin potentiates the therapeutic effect of memantine against central STZ-induced spatial learning and memory deficit. ( Bahramian, A; Moosavi, M; Namavar, MR; Rastegar, K, 2016) |
"Memantine or saline were given daily for 13 days starting from the day of OA injection." | 1.43 | MEMANTINE ATTENUATES THE OKADAIC ACID INDUCED SHORT-TERM SPATIAL MEMORY IMPAIRMENT AND HIPPOCAMPAL CELL LOSS IN RATS. ( Beselia, G; Burjanadze, M; Chighladze, M; Dashniani, M; Kruashvili, L, 2016) |
"Memory loss is one of the key features of cognitive impairment in either aging, Mild Cognitive Impairment (MCI) or dementia." | 1.40 | Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged Octodon degus. ( Blin, O; Bordet, R; Canovi, M; Cella, M; Estrada, C; Fernández-Villalba, E; Gobbi, M; Gonzalez-Cuello, A; Guiso, G; Herrero, MT; Lamberty, Y; Lopez, D; Pifferi, F; Richardson, JC; Ros, CM; Tarragon, E, 2014) |
"Pre-treatment with memantine did not prevent MDMA-induced memory impairment in these two tasks." | 1.40 | Memory and mood during MDMA intoxication, with and without memantine pretreatment. ( de la Torre, R; de Sousa Fernandes Perna, EB; Farre, M; Heckman, P; Kuypers, KP; Ramaekers, JG; Theunissen, EL, 2014) |
"Memantine was also effective in these tests and concomitant administration of subeffective doses of ZSET1446 and memantine significantly ameliorated the cognitive performance in the novel object recognition task in both mice and rats." | 1.39 | Combination effects of ZSET1446/ST101 with memantine on cognitive function and extracellular acetylcholine in the hippocampus. ( Hino, M; Takeda, K; Yamaguchi, Y, 2013) |
"Alzheimer's disease is characterized by a progressive decline in cognitive function and involves β-amyloid (Aβ) in its pathogenesis." | 1.39 | Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine. ( Matsuoka, N; Nagakura, A; Shitaka, Y; Yarimizu, J, 2013) |
"Cognitive impairments observed in Cushing's disease are reviewed as well as the deleterious effects of glucocorticoid treatments on episodic memory." | 1.38 | [Effects of glucocorticoids administration on memory. Cognitive impairment in Cushing's disease]. ( Berney, P; Martin-Du Pan, RC, 2012) |
"Memantine treatment improved spatial and recognition memory performance in the Ts65Dn mice, though not to the level of normosomic littermate controls." | 1.37 | Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. ( Bimonte-Nelson, H; Boger, H; Granholm, AC; Lockrow, J, 2011) |
" A group of male and female rats was treated with one of these compounds for 15 days, after which a single dosage of scopolamine was administered." | 1.37 | Comparative protective action of curcumin, memantine and diclofenac against scopolamine-induced memory dysfunction. ( Ali, EH; Arafa, NM, 2011) |
"Memantine has been approved to treat moderate to severe Alzheimer disease (AD), which is characterized by cognitive impairment." | 1.37 | Memantine attenuates the impairment of spatial learning and memory of pentylenetetrazol-kindled rats. ( An, LW; Duan, RS; Jia, LJ; Li, ZP; Wang, WP; Zhen, JL, 2011) |
"Memantine was recommended for all patients with mental disorders." | 1.37 | [Mental disorders following delirium tremens]. ( Damulin, IV; Ianushkevich, MV; Mendelevich, SV; Savchenkov, VA; Sivolap, IuP, 2011) |
"We treated rats with transient cerebral ischemia with oligomeric forms of Abeta (Abeta oligomers), including dimers, trimers, and tetramers, intracerebroventricularly." | 1.36 | Dynamin 1 depletion and memory deficits in rats treated with Abeta and cerebral ischemia. ( Fujino, M; Fujiwara, M; Ii, M; Iwasaki, K; Katsurabayashi, S; Mishima, K; Nogami, A; Takasaki, K; Watanabe, T; Yamagata, N, 2010) |
"Memantine-treated rats showed normal recognition memory while the saline group showed long-term recognition memory deficits." | 1.34 | Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats. ( Budni, P; Constantino, L; Dal-Pizzol, F; Dornelles, A; Garcia, VA; Martins de Lima, MN; Pietá Dias, C; Presti-Torres, J; Rewsaat Guimarães, M; Schröder, N; Siciliani Scalco, F, 2007) |
Research
Studies (68)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (1.47) | 18.2507 |
2000's | 10 (14.71) | 29.6817 |
2010's | 51 (75.00) | 24.3611 |
2020's | 6 (8.82) | 2.80 |
Authors
Authors | Studies |
---|---|
Das, A | 1 |
Brasseux, S | 1 |
Anoush, M | 1 |
Bijani, S | 1 |
Moslemifar, F | 1 |
Jahanpour, F | 1 |
Kalantari-Hesari, A | 1 |
Hosseini, MJ | 1 |
Jürgenson, M | 1 |
Zharkovskaja, T | 1 |
Noortoots, A | 1 |
Morozova, M | 1 |
Beniashvili, A | 1 |
Zapolski, M | 1 |
Zharkovsky, A | 1 |
Ferragud, A | 1 |
Velázquez-Sánchez, C | 1 |
Abdullatif, AA | 1 |
Sabino, V | 1 |
Cottone, P | 1 |
Couly, S | 1 |
Denus, M | 1 |
Bouchet, M | 1 |
Rubinstenn, G | 1 |
Maurice, T | 2 |
Mishra, SK | 1 |
Hidau, MK | 1 |
Rai, S | 4 |
Shimoyama, T | 1 |
Aoki, Y | 1 |
Kaneda, M | 1 |
Han, LK | 1 |
Michihara, S | 1 |
Takahashi, R | 1 |
Budni, J | 1 |
Feijó, DP | 1 |
Batista-Silva, H | 1 |
Garcez, ML | 1 |
Mina, F | 1 |
Belletini-Santos, T | 1 |
Krasilchik, LR | 1 |
Luz, AP | 1 |
Schiavo, GL | 1 |
Quevedo, J | 1 |
Havolli, E | 1 |
Hill, MD | 1 |
Godley, A | 1 |
Goetghebeur, PJ | 1 |
Rahman, A | 1 |
Lamberty, Y | 2 |
Schenker, E | 1 |
Cella, M | 2 |
Languille, S | 1 |
Bordet, R | 2 |
Richardson, J | 1 |
Pifferi, F | 2 |
Aujard, F | 1 |
Bellman, S | 1 |
Zhang, D | 1 |
Zhou, W | 1 |
Lam, TT | 1 |
Weng, C | 1 |
Bronk, L | 1 |
Ma, D | 1 |
Wang, Q | 1 |
Duman, JG | 1 |
Dougherty, PM | 1 |
Grosshans, DR | 1 |
Amidfar, M | 1 |
Kim, YK | 1 |
Wiborg, O | 1 |
Wang, X | 2 |
Yu, H | 1 |
You, J | 1 |
Wang, C | 1 |
Feng, C | 1 |
Liu, Z | 1 |
Li, Y | 1 |
Wei, R | 1 |
Xu, S | 1 |
Zhao, R | 1 |
Wu, X | 1 |
Zhang, G | 1 |
Nirogi, R | 1 |
Abraham, R | 1 |
Benade, V | 1 |
Medapati, RB | 1 |
Jayarajan, P | 1 |
Bhyrapuneni, G | 1 |
Muddana, N | 1 |
Mekala, VR | 1 |
Subramanian, R | 1 |
Shinde, A | 1 |
Kambhampati, R | 1 |
Jasti, V | 1 |
Louis, C | 2 |
Llopis, K | 1 |
Danober, L | 1 |
Panayi, F | 1 |
Lestage, P | 2 |
Beracochea, D | 2 |
Göl, M | 1 |
Demiryürek, Ş | 1 |
Kaplan, DS | 1 |
Saracaloğlu, A | 1 |
Örkmez, M | 1 |
Demiryürek, AT | 1 |
Al-Hazmi, MA | 1 |
Rawi, SM | 1 |
Arafa, NM | 2 |
Wagas, A | 1 |
Montasser, AO | 1 |
Cole, PD | 1 |
Vijayanathan, V | 1 |
Ali, NF | 1 |
Wagshul, ME | 1 |
Tanenbaum, EJ | 1 |
Price, J | 1 |
Dalal, V | 1 |
Gulinello, ME | 1 |
Borre, YE | 1 |
Panagaki, T | 1 |
Koelink, PJ | 1 |
Morgan, ME | 1 |
Hendriksen, H | 1 |
Garssen, J | 1 |
Kraneveld, AD | 1 |
Olivier, B | 1 |
Oosting, RS | 1 |
Yamaguchi, Y | 1 |
Takeda, K | 1 |
Hino, M | 1 |
He, D | 2 |
Zhang, Y | 1 |
Dong, S | 1 |
Wang, D | 1 |
Gao, X | 1 |
Zhou, H | 2 |
Schneider, LS | 1 |
Mangialasche, F | 1 |
Andreasen, N | 1 |
Feldman, H | 1 |
Giacobini, E | 1 |
Jones, R | 1 |
Mantua, V | 1 |
Mecocci, P | 1 |
Pani, L | 1 |
Winblad, B | 1 |
Kivipelto, M | 1 |
de Sousa Fernandes Perna, EB | 1 |
Theunissen, EL | 1 |
Kuypers, KP | 1 |
Heckman, P | 1 |
de la Torre, R | 1 |
Farre, M | 1 |
Ramaekers, JG | 1 |
Akaishi, T | 1 |
Tarragon, E | 1 |
Lopez, D | 1 |
Estrada, C | 1 |
Gonzalez-Cuello, A | 1 |
Ros, CM | 1 |
Canovi, M | 1 |
Guiso, G | 1 |
Gobbi, M | 1 |
Fernández-Villalba, E | 1 |
Blin, O | 1 |
Richardson, JC | 1 |
Herrero, MT | 1 |
Zhu, G | 1 |
Li, J | 1 |
He, L | 1 |
Hong, X | 1 |
Gharedaghi, MH | 1 |
Rahimian, R | 1 |
Dehpour, AR | 1 |
Yousefzadeh-Fard, Y | 1 |
Mohammadi-Farani, A | 1 |
Higuera, C | 1 |
Gardiner, KJ | 1 |
Cios, KJ | 1 |
Veerman, SR | 2 |
Schulte, PF | 2 |
Smith, JD | 1 |
de Haan, L | 2 |
Marszalek-Grabska, M | 1 |
Gibula-Bruzda, E | 1 |
Jenda, M | 1 |
Gawel, K | 1 |
Kotlinska, JH | 1 |
Dashniani, M | 1 |
Chighladze, M | 1 |
Burjanadze, M | 1 |
Beselia, G | 1 |
Kruashvili, L | 1 |
Bahramian, A | 1 |
Rastegar, K | 1 |
Namavar, MR | 1 |
Moosavi, M | 1 |
Deijen, JB | 1 |
Moriguchi, S | 1 |
Ishizuka, T | 1 |
Yabuki, Y | 1 |
Shioda, N | 1 |
Sasaki, Y | 1 |
Tagashira, H | 1 |
Yawo, H | 1 |
Yeh, JZ | 1 |
Sakagami, H | 1 |
Narahashi, T | 1 |
Fukunaga, K | 1 |
Cheng, J | 1 |
Liu, X | 1 |
Cao, L | 1 |
Zhang, T | 1 |
Li, H | 1 |
Lin, W | 1 |
Burke, SN | 1 |
Maurer, AP | 1 |
Yang, Z | 1 |
Navratilova, Z | 1 |
Barnes, CA | 2 |
Wroolie, TE | 1 |
Kenna, HA | 1 |
Williams, KE | 1 |
Powers, BN | 1 |
Holcomb, M | 1 |
Lazzeroni, L | 1 |
Rasgon, NL | 1 |
Kamat, PK | 4 |
Tota, S | 3 |
Saxena, G | 1 |
Shukla, R | 4 |
Nath, C | 4 |
Watanabe, T | 1 |
Iwasaki, K | 1 |
Takasaki, K | 1 |
Yamagata, N | 1 |
Fujino, M | 1 |
Nogami, A | 1 |
Ii, M | 1 |
Katsurabayashi, S | 1 |
Mishima, K | 1 |
Fujiwara, M | 1 |
Lockrow, J | 1 |
Boger, H | 1 |
Bimonte-Nelson, H | 1 |
Granholm, AC | 1 |
Camarasa, J | 1 |
Rodrigo, T | 1 |
Pubill, D | 1 |
Escubedo, E | 1 |
Mayeux, R | 1 |
Isik, AT | 1 |
Vandesquille, M | 1 |
Krazem, A | 1 |
Ali, EH | 1 |
Terry, AV | 1 |
Callahan, PM | 1 |
Hall, B | 1 |
Webster, SJ | 1 |
Jia, LJ | 1 |
Wang, WP | 1 |
Li, ZP | 1 |
Zhen, JL | 1 |
An, LW | 1 |
Duan, RS | 1 |
Saab, BJ | 1 |
Luca, RM | 1 |
Yuen, WB | 1 |
Saab, AM | 1 |
Roder, JC | 1 |
Guo, D | 1 |
Hao, Z | 1 |
Wu, B | 1 |
Ponce-Lopez, T | 1 |
Liy-Salmeron, G | 1 |
Hong, E | 1 |
Meneses, A | 1 |
Swarnkar, S | 1 |
Sivolap, IuP | 1 |
Damulin, IV | 1 |
Mendelevich, SV | 1 |
Savchenkov, VA | 1 |
Ianushkevich, MV | 1 |
Ali, S | 1 |
Najmi, AK | 1 |
Wang, L | 1 |
Chiang, HC | 1 |
Wu, W | 1 |
Liang, B | 1 |
Xie, Z | 1 |
Yao, X | 1 |
Ma, W | 1 |
Du, S | 1 |
Zhong, Y | 1 |
Martin-Du Pan, RC | 1 |
Berney, P | 1 |
Nagakura, A | 1 |
Shitaka, Y | 1 |
Yarimizu, J | 1 |
Matsuoka, N | 1 |
Kowal, C | 1 |
DeGiorgio, LA | 1 |
Nakaoka, T | 1 |
Hetherington, H | 1 |
Huerta, PT | 1 |
Diamond, B | 1 |
Volpe, BT | 1 |
Yamada, K | 1 |
Takayanagi, M | 1 |
Kamei, H | 1 |
Nagai, T | 1 |
Dohniwa, M | 1 |
Kobayashi, K | 1 |
Yoshida, S | 1 |
Ohhara, T | 1 |
Takuma, K | 1 |
Nabeshima, T | 1 |
Creeley, C | 1 |
Wozniak, DF | 1 |
Labruyere, J | 1 |
Taylor, GT | 1 |
Olney, JW | 1 |
Nakamura, S | 1 |
Murayama, N | 1 |
Noshita, T | 1 |
Katsuragi, R | 1 |
Ohno, T | 1 |
Rosi, S | 1 |
Vazdarjanova, A | 1 |
Ramirez-Amaya, V | 1 |
Worley, PF | 1 |
Wenk, GL | 2 |
Owley, T | 1 |
Salt, J | 1 |
Guter, S | 1 |
Grieve, A | 1 |
Walton, L | 1 |
Ayuyao, N | 1 |
Leventhal, BL | 1 |
Cook, EH | 1 |
Pietá Dias, C | 1 |
Martins de Lima, MN | 1 |
Presti-Torres, J | 1 |
Dornelles, A | 1 |
Garcia, VA | 1 |
Siciliani Scalco, F | 1 |
Rewsaat Guimarães, M | 1 |
Constantino, L | 1 |
Budni, P | 1 |
Dal-Pizzol, F | 1 |
Schröder, N | 1 |
Parsons, CG | 1 |
Stöffler, A | 1 |
Danysz, W | 2 |
Mobley, SL | 1 |
Clinical Trials (2)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
EMRESERVA A Program to Enhace Cognitive Reserve in Patients With Multiple Scleorisis[NCT05546424] | 58 participants (Anticipated) | Observational | 2022-05-19 | Recruiting | |||
Phase II Multicenter 16-Week Randomized Double Blind Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Adolescents and Young Adults With Down Syndrome[NCT02304302] | Phase 2 | 160 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Adaptive/Behavioral Functioning of the Participants as Assessed by Change in Score on the Scales of Independent Behavior-Revised (SIB-R)
This is a measure of adaptive functioning that integrates information from 13 different domains (e.g., gross motor, social interaction, eating, toileting, dressing, personal self-care, etc.). It is in a questionnaire format, which a caregiver can complete while the participant is being tested. Standard scores for all indices will be derived from age norms that extend from birth to age 80, as these were used as dependent variables. We report here on the Broad Independence Score recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value of the SIB-R Score Scale in this study was -24 (this number is below 0 because -24 was the minimum value for the worst performing participant in the trial) and the maximum value of this scale is 153; higher scores mean better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | 6.88 |
Memantine | 3.23 |
Efficacy of the Drug Memantine as Assessed by Change in Score on the California Verbal Learning Test-II (CVLT-II) Short Form Total Free Recall
The primary efficacy measure is focused on episodic memory. The CVLT-II short form assesses supraspan word learning ability as an index of episodic verbal long-term memory. We hypothesize that treatment with memantine will produce significant improvements in this test. The main dependent variable selected, based on prior literature was the total number of target items correct summed across learning trials 1-4. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). Scale Range: from 0 to 36; higher scores represent better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | 3.3 |
Memantine | 3.49 |
Efficacy of the Drug Memantine as Assessed by Change in Score on the Paired Associates Learning (PAL) From the Cambridge Neuropsychological Test Automated Battery (CANTAB)
This is a measure of non-verbal memory that requires the participant to learn associations between an abstract visual pattern and its location. Two dependent variables have been selected: Total number of items correct on the first trial of each stage, and total number of stages completed. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value of the PAL Memory Score Scale is 0 and the maximum value is 21; higher scores mean better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | 1 |
Memantine | 0.67 |
Efficacy of the Drug Memantine as Assessed by Change in Score on the Pattern Recognition Memory (PRM; Part of the Cambridge Neuropsychological Test Automated Battery -- CANTAB)
This is a measure of non-verbal memory. Total number correct across the two series of items presented was used as the dependent variable. We used the PRM total scale in this study, which represents the sum of the PRM correct scores (ranging from 0 to 24) and the PRM delayed scores (ranging from 0 to 24). Therefore, the range of the PRM total scale is from 0 to 48; higher values mean better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | 0.45 |
Memantine | -0.05 |
Efficacy of the Drug Memantine as Assessed by Change in Score on the Recall of Digits Forward (From the Differential Ability Scales; DAS-II)
This is a measure of rote short-term verbal memory. Total number of items correct were used as the dependent variable. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value for this scale is 0 and the maximum value is 38; higher scores mean a better outcome. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | 0.03 |
Memantine | -0.01 |
Efficacy of the Drug Memantine as Assessed by Change in Score on the Spatial Span (Part of the Cambridge Neuropsychological Test Automated Battery -- CANTAB)
This measure is a computerized version of the Corsi Blocks task, a long-standing neuropsychological test. The main dependent variables selected for this test was the span length, which is the longest sequence of numbers recalled accurately. The minimum value of the Spatial Span Length Score Scale is 0 and the maximum value is 9; higher scores mean better outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | 0.13 |
Memantine | 0.03 |
Efficacy of the Drug Memantine as Assessed by Change in Score on the Spatial Working Memory (Part of the Cambridge Neuropsychological Test Automated Battery -- CANTAB)
"The test requires participants to search under a series of colored boxes to locate a blue token hidden underneath one of them. During a series of trials, the participant is told that the token will be in a new location each time and that they should not go back to a location he or she has looked in previously. The main dependent variable was the total number of errors (between errors), which indexes the number of times a participant went back to a box where a token had already been found, lower scores mean better performance. The minimum value of the Spatial Working Memory scale is 0 and the maximum value is 137 (which was computed as the equivalent to -4 standard deviations from the mean of this measure); higher scores mean worse outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2)." (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | -0.09 |
Memantine | -1.4 |
Efficacy of the Drug Memantine as Assessed by Change in Score on the The Go - No Go Task
"This is a measure of inhibitory control, often used as a marker for prefrontal-striatal function integrity. Specifically, it measures the participant's ability to inhibit pre-potent behavioral responses that have been established by provision of prior go or no-go cues in a classical conditioning paradigm. The main dependent variables selected was speed of response of execution to Go targets. The minimum value of the speed of response of execution to Go targets is 280 milliseconds (ms) and the maximum value is 1000 ms; higher scores mean worse outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2)." (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | ms (Mean) |
---|---|
Placebo | -2.52 |
Memantine | 0.22 |
Intellectual Functioning of the Participants as Assessed by Change in Score on the Matrices Subtest of the Differential Ability Scales-II (DAS-II)
This test provides a measure of non-verbal reasoning ability that requires subjects to visually inspect a matrix of 4 or 9 pictures that has a missing piece. Participants have to infer a rule or pattern in the stimuli and select the appropriate response from a range of 4-6 possibilities. Since age norms are not available for individuals older than 17y11m, the ability score will be used as the dependent variable. This is an intermediate score based on Rasch modeling that corrects for different items set being administered to participants. The minimum value of the DAS-II Rasch Score Scale is 0 and the maximum value is 153; higher scores mean better outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | 0.75 |
Memantine | 2.66 |
Linguistic Functioning of the Participants as Assessed by Change in Score on the Peabody Picture Vocabulary Test-IV (PPVT-IV)
This is a measure of receptive semantics, whereby the participant is asked to point to a picture (out of 4) that corresponds to a word spoken by the examiner. As this test has a 0.85 correlation with composite measures of Verbal IQ (i.e. from the Wechsler Intelligence Scale series), it can be used in conjunction with the Matrices subtest to estimate overall intellectual functioning. The total number of items correct was used as the dependent variable, following the administration manual's rules for basals and ceilings. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value for this scale is 0 and the maximum value is 192, higher scores mean a better outcome. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | 4.46 |
Memantine | 5.63 |
Linguistic Functioning of the Participants as Assessed by Change in Score on the Test for Reception of Grammar 2nd Edition (TROG-II)
This is a measure of receptive syntax skills (Bishop, 1983). Participants are asked to point to a picture (out of 4) that corresponds to a phrase or sentence spoken by the examiner. The total number of items correct (rather than blocks passed) will be used as the dependent variable, following the administration manual's ceiling rule. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value of the scores is 0 and the maximum value is 40; with higher scores considered to be a better outcome. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | 0.49 |
Memantine | 0.89 |
Safety and Tolerability of the Drug Memantine as Assessed by Change in QTc Interval
Incidence of adverse events was monitored by clinical history, physical examinations, electrocardiograms (ECGs), clinical laboratory tests, the Screen for Childhood Anxiety Related Emotional Disorders (SCARED). Here, we report the analysis of the effect of memantine treatment on QTc intervals because of its clinical importance for this analysis for potential drug toxicity. QTc intervals ≥ 450 ms are generally considered long, and drug-induced QTc interval prolongations ≥ 60 ms are generally considered clinically relevant. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | ms (Mean) |
---|---|
Placebo | -1.30 |
Memantine | -0.11 |
Reviews
9 reviews available for memantine and Memory Disorders
Article | Year |
---|---|
Pharmacological treatment for memory disorder in multiple sclerosis.
Topics: Adult; Donepezil; Ginkgo biloba; Humans; Indans; Memantine; Memory Disorders; Multiple Sclerosis; Ne | 2017 |
Pharmacological treatment for memory disorder in multiple sclerosis.
Topics: Adult; Donepezil; Ginkgo biloba; Humans; Indans; Memantine; Memory Disorders; Middle Aged; Multiple | 2013 |
Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014.
Topics: Alzheimer Disease; Biomarkers; Cholinesterase Inhibitors; Dopamine Agents; Drug Monitoring; Humans; | 2014 |
[Memory-enhancing drugs].
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cyclic AMP Response Element-Binding Pro | 2014 |
Clinical practice. Early Alzheimer's disease.
Topics: Age of Onset; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Diagnosis, Differential; Disease P | 2010 |
Late onset Alzheimer's disease in older people.
Topics: Age Factors; Age of Onset; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Hu | 2010 |
Alzheimer's disease and age-related memory decline (preclinical).
Topics: Aging; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Histamine H3 A | 2011 |
Pharmacologic treatment for memory disorder in multiple sclerosis.
Topics: Adult; Donepezil; Ginkgo biloba; Humans; Indans; Memantine; Memory Disorders; Middle Aged; Multiple | 2011 |
Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.
Topics: Alzheimer Disease; Dose-Response Relationship, Drug; Excitatory Amino Acid Agents; Homeostasis; Huma | 2007 |
Trials
3 trials available for memantine and Memory Disorders
Article | Year |
---|---|
Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognitive Dysfunction; Cross-Over Studies; Double-Blind Meth | 2016 |
Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognitive Dysfunction; Drug Resistance; Drug Synergism; Drug | 2017 |
Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study.
Topics: Aged; Alzheimer Disease; Apolipoprotein E4; Cognition; Dementia; Excitatory Amino Acid Antagonists; | 2009 |
Other Studies
56 other studies available for memantine and Memory Disorders
Article | Year |
---|---|
Improvement in Memory Deficits With Memantine in Mania Secondary to Traumatic Brain Injury and Preexisting Perinatal Birth Injury.
Topics: Birth Injuries; Brain Injuries, Traumatic; Humans; Male; Mania; Memantine; Memory Disorders | 2021 |
Edaravone Improves Streptozotocin-Induced Memory Impairment via Alleviation of Behavioral Dysfunction, Oxidative Stress, Inflammation, and Histopathological Parameters.
Topics: Alzheimer Disease; Animals; Antioxidants; Disease Models, Animal; Donepezil; Edaravone; Inflammation | 2023 |
Effects of the drug combination memantine and melatonin on impaired memory and brain neuronal deficits in an amyloid-predominant mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cholineste | 2019 |
Withdrawal from Extended, Intermittent Access to A Highly Palatable Diet Impairs Hippocampal Memory Function and Neurogenesis: Effects of Memantine.
Topics: Animals; Behavior, Animal; Body Weight; Diet; Disease Models, Animal; Eating; Feeding and Eating Dis | 2020 |
Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Behavior, Animal; Disease Models, Animal | 2021 |
Memantine treatment exerts an antidepressant-like effect by preventing hippocampal mitochondrial dysfunction and memory impairment via upregulation of CREB/BDNF signaling in the rat model of chronic unpredictable stress-induced depression.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Element-Bindi | 2021 |
[Effects of Yokukansankachimpihange on Memantine-induced Dizziness in Mice with Memory Impairment].
Topics: Administration, Oral; Alzheimer Disease; Animals; Disease Models, Animal; Dizziness; Drug Therapy, C | 2021 |
Lithium and memantine improve spatial memory impairment and neuroinflammation induced by β-amyloid 1-42 oligomers in rats.
Topics: Amyloid beta-Peptides; Animals; Brain; Inflammation; Interleukin-4; Lithium; Male; Memantine; Memory | 2017 |
Spatial recognition test: A novel cognition task for assessing topographical memory in mice.
Topics: Alzheimer Disease; Animals; Cognition; Disease Models, Animal; Donepezil; Indans; Levetiracetam; Mal | 2017 |
Effects of acute administration of donepezil or memantine on sleep-deprivation-induced spatial memory deficit in young and aged non-human primate grey mouse lemurs (Microcebus murinus).
Topics: Aging; Alzheimer Disease; Animals; Cheirogaleidae; Disease Models, Animal; Donepezil; Indans; Male; | 2017 |
Radiation induces age-dependent deficits in cortical synaptic plasticity.
Topics: Age Factors; Animals; Cranial Irradiation; Excitatory Amino Acid Antagonists; Hippocampus; Long-Term | 2018 |
Effectiveness of memantine on depression-like behavior, memory deficits and brain mRNA levels of BDNF and TrkB in rats subjected to repeated unpredictable stress.
Topics: Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Depression; Depressive Dis | 2018 |
Memantine can improve chronic ethanol exposure-induced spatial memory impairment in male C57BL/6 mice by reducing hippocampal apoptosis.
Topics: Animals; Apoptosis; Dose-Response Relationship, Drug; Ethanol; Excitatory Amino Acid Antagonists; Hi | 2018 |
SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization.
Topics: Acetylcholine; Animals; Behavior, Animal; Brain; Brain Waves; CHO Cells; Cricetulus; Culture Media, | 2019 |
New procognitive enhancers acting at the histamine H3 and AMPA receptors reverse natural forgetting in mice: comparisons with donepezil and memantine in the object recognition task.
Topics: Animals; Azabicyclo Compounds; Benzamides; Benzoxazines; Cognition; Donepezil; Histamine Agonists; M | 2019 |
N-(p-amylcinnamoyl) anthranilic acid attenuates remedial effects of memantine on memory deficits following intracerebroventricular streptozotocin administration in rats.
Topics: Animals; Maze Learning; Memantine; Memory Disorders; ortho-Aminobenzoates; Oxidative Stress; Random | 2019 |
The potent effects of ginseng root extract and memantine on cognitive dysfunction in male albino rats.
Topics: Acetylcholinesterase; Animals; Brain; Dopamine; Dose-Response Relationship, Drug; gamma-Aminobutyric | 2015 |
Memantine protects rats treated with intrathecal methotrexate from developing spatial memory deficits.
Topics: Animals; Cognition; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Injections, S | 2013 |
Neuroprotective and cognitive enhancing effects of a multi-targeted food intervention in an animal model of neurodegeneration and depression.
Topics: Animals; Atrophy; Cell Death; Cognition Disorders; Depressive Disorder; Disease Models, Animal; Hipp | 2014 |
Combination effects of ZSET1446/ST101 with memantine on cognitive function and extracellular acetylcholine in the hippocampus.
Topics: Acetylcholine; Administration, Oral; Animals; Cognition; Cognition Disorders; Dihydro-beta-Erythroid | 2013 |
Memory and mood during MDMA intoxication, with and without memantine pretreatment.
Topics: Affect; Amphetamine-Related Disorders; Central Nervous System Stimulants; Double-Blind Method; Femal | 2014 |
Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged Octodon degus.
Topics: Aging; Animals; Female; Maze Learning; Memantine; Memory Disorders; Memory, Short-Term; Neuropsychol | 2014 |
MPTP-induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF-TrkB pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Ag | 2015 |
Dinitrobenzene sulphonic acid-induced colitis impairs spatial recognition memory in mice: roles of N-methyl D-aspartate receptors and nitric oxide.
Topics: Animals; Avoidance Learning; Benzenesulfonates; Cognition; Colitis; Dizocilpine Maleate; Guanidines; | 2015 |
Self-Organizing Feature Maps Identify Proteins Critical to Learning in a Mouse Model of Down Syndrome.
Topics: Animals; Cluster Analysis; Disease Models, Animal; Down Syndrome; Gene Expression Regulation; Humans | 2015 |
Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments.
Topics: Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Drug S | 2016 |
Memantine improves memory impairment and depressive-like behavior induced by amphetamine withdrawal in rats.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Antidepressive Agents; Central Nervous System S | 2016 |
MEMANTINE ATTENUATES THE OKADAIC ACID INDUCED SHORT-TERM SPATIAL MEMORY IMPAIRMENT AND HIPPOCAMPAL CELL LOSS IN RATS.
Topics: Animals; Cell Count; Hippocampus; Male; Memantine; Memory Disorders; Memory, Short-Term; Neuroprotec | 2016 |
Insulin potentiates the therapeutic effect of memantine against central STZ-induced spatial learning and memory deficit.
Topics: Animals; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 2016 |
Blockade of the K
Topics: Alzheimer Disease; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Dendrites; Disease M | 2018 |
Neo-adjuvant chemotherapy with cisplatin induces low expression of NMDA receptors and postoperative cognitive impairment.
Topics: Animals; Cisplatin; Cognition; Cognitive Dysfunction; Female; Hippocampus; Learning; Maze Learning; | 2017 |
Glutamate receptor-mediated restoration of experience-dependent place field expansion plasticity in aged rats.
Topics: Age Factors; Aging; Analysis of Variance; Animals; Behavior, Animal; Conditioning, Psychological; Di | 2008 |
Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity.
Topics: Animals; Brain; Calcium Signaling; Cholinesterase Inhibitors; Dementia; Disease Models, Animal; Done | 2010 |
Dynamin 1 depletion and memory deficits in rats treated with Abeta and cerebral ischemia.
Topics: Amyloid beta-Peptides; Animals; Dynamin I; Excitatory Amino Acid Antagonists; Hippocampus; Ischemic | 2010 |
Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.
Topics: Animals; Brain; Brain-Derived Neurotrophic Factor; Cholinergic Fibers; Chromosomes, Mammalian; Disea | 2011 |
Memantine is a useful drug to prevent the spatial and non-spatial memory deficits induced by methamphetamine in rats.
Topics: Animals; Body Temperature; Dopamine Uptake Inhibitors; Hippocampus; Male; Maze Learning; Memantine; | 2010 |
S 18986 reverses spatial working memory impairments in aged mice: comparison with memantine.
Topics: Aging; Alzheimer Disease; Animals; Behavior, Animal; Benzothiadiazines; Excitatory Amino Acid Antago | 2011 |
Comparative protective action of curcumin, memantine and diclofenac against scopolamine-induced memory dysfunction.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cholinergic Antagonists; Curcumin; Diclofenac; Exc | 2011 |
Memantine attenuates the impairment of spatial learning and memory of pentylenetetrazol-kindled rats.
Topics: Animals; Behavior, Animal; Convulsants; Excitatory Amino Acid Antagonists; Kindling, Neurologic; Lea | 2011 |
Memantine affects cognitive flexibility in the Morris water maze.
Topics: Animals; Cognition; Male; Maze Learning; Memantine; Memory Disorders; Mice; Reaction Time | 2011 |
Lithium, phenserine, memantine and pioglitazone reverse memory deficit and restore phospho-GSK3β decreased in hippocampus in intracerebroventricular streptozotocin induced memory deficit model.
Topics: Animals; Conditioning, Classical; Disease Models, Animal; Enzyme Inhibitors; Glycogen Synthase Kinas | 2011 |
A study on neuroinflammatory marker in brain areas of okadaic acid (ICV) induced memory impaired rats.
Topics: Animals; Behavior, Animal; Biomarkers; Blotting, Western; Donepezil; Excitatory Amino Acid Antagonis | 2012 |
[Mental disorders following delirium tremens].
Topics: Adult; Alcohol Withdrawal Delirium; Cognition Disorders; Dopamine Agents; Humans; Male; Memantine; M | 2011 |
Okadaic acid induced neurotoxicity leads to central cholinergic dysfunction in rats.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Biomarkers; Donepezil; Gene Expression Regulation; Hip | 2012 |
Epidermal growth factor receptor is a preferred target for treating amyloid-β-induced memory loss.
Topics: Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Blotting, Western; Chlorocebus aethio | 2012 |
A study on neuroinflammation and NMDA receptor function in STZ (ICV) induced memory impaired rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Cytokines; Disease Models, Animal; Dose-Res | 2013 |
[Effects of glucocorticoids administration on memory. Cognitive impairment in Cushing's disease].
Topics: Aged, 80 and over; Betamethasone; Cognition Disorders; Female; Glucocorticoids; Humans; Injections, | 2012 |
Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine.
Topics: Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Cyclic AMP Response Element-Binding Pr | 2013 |
Cognition and immunity; antibody impairs memory.
Topics: Animals; Blood-Brain Barrier; Cognition; Cognition Disorders; Fluorescent Antibody Technique; Immune | 2004 |
Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats.
Topics: Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Conditioning, Operant; Donepezil; Drug Ad | 2005 |
Low doses of memantine disrupt memory in adult rats.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Brain Edema; Disease Models, Animal; Excitatory Am | 2006 |
Cognitive dysfunction induced by sequential injection of amyloid-beta and ibotenate into the bilateral hippocampus; protection by memantine and MK-801.
Topics: Amyloid beta-Peptides; Animals; Disease Models, Animal; Dizocilpine Maleate; Excitatory Amino Acid A | 2006 |
Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat.
Topics: Animals; Behavior, Animal; Cytoskeletal Proteins; Disease Models, Animal; Dose-Response Relationship | 2006 |
A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders.
Topics: Child; Child Behavior Disorders; Child Development Disorders, Pervasive; Child, Preschool; Cognition | 2006 |
Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats.
Topics: Aging; Animals; Behavior, Animal; Excitatory Amino Acid Antagonists; Exploratory Behavior; Male; Mem | 2007 |
Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat.
Topics: Acetylcholine; Animals; Basal Ganglia; Behavior, Animal; Cerebral Cortex; Choline O-Acetyltransferas | 1994 |